Abstract

Disordered hepatic glucagon response contributes to hyperglycemia in diabetes. The regulators involved in glucagon response are less understood. This work aims to investigate the roles of mitochondrial β-oxidation enzyme HADHA and its downstream ketone bodies in hepatic glucagon response. Here we show that glucagon challenge impairs expression of HADHA. Liver-specific HADHA overexpression reversed hepatic gluconeogenesis in mice, while HADHA knockdown augmented glucagon response. Stable isotope tracing shows that HADHA promotes ketone body production via β-oxidation. The ketone body β-hydroxybutyrate (BHB) but not acetoacetate suppresses gluconeogenesis by selectively inhibiting HDAC7 activity via interaction with Glu543 site to facilitate FOXO1 nuclear exclusion. In HFD-fed mice, HADHA overexpression improved metabolic disorders, and these effects are abrogated by knockdown of BHB-producing enzyme. In conclusion, BHB is responsible for the inhibitory effect of HADHA on hepatic glucagon response, suggesting that HADHA activation or BHB elevation by pharmacological intervention hold promise in treating diabetes.

Disordered hepatic glucagon response contributes to hyperglycemia in diabetes via gluconeogenesis. Here the authors report that the mitochondrial β-oxidation enzyme HADHA promotes β-hydroxybutyrate production, which negatively regulates hepatic gluconeogenesis during glucagon challenge by targeting HDAC7 in mice.

Details

Title
The mitochondrial β-oxidation enzyme HADHA restrains hepatic glucagon response by promoting β-hydroxybutyrate production
Author
Pan, An 1 ; Xiao-Meng, Sun 1 ; Feng-Qing, Huang 1 ; Jin-Feng, Liu 2   VIAFID ORCID Logo  ; Yuan-Yuan, Cai 1 ; Wu, Xin 1 ; Alolga, Raphael N 2 ; Li, Ping 1 ; Bao-Lin, Liu 1 ; Liu, Qun 3   VIAFID ORCID Logo  ; Lian-Wen, Qi 3   VIAFID ORCID Logo 

 State Key Laboratory of Natural Medicines, School of Traditional Chinese Pharmacy, China Pharmaceutical University, Nanjing, China (GRID:grid.254147.1) (ISNI:0000 0000 9776 7793) 
 Clinical Metabolomics Center, China Pharmaceutical University, Nanjing, China (GRID:grid.254147.1) (ISNI:0000 0000 9776 7793) 
 State Key Laboratory of Natural Medicines, School of Traditional Chinese Pharmacy, China Pharmaceutical University, Nanjing, China (GRID:grid.254147.1) (ISNI:0000 0000 9776 7793); Clinical Metabolomics Center, China Pharmaceutical University, Nanjing, China (GRID:grid.254147.1) (ISNI:0000 0000 9776 7793) 
Publication year
2022
Publication date
2022
Publisher
Nature Publishing Group
e-ISSN
20411723
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2621100437
Copyright
© The Author(s) 2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.